Dr. Saba's Laboratory
Pediatric Malignancies
Colon Cancer
Muscular Dystrophy
T Cell Trafficking
SPL Insufficiency Syndrome (SPLIS)
Scientists & Staff

Phone: 510-450-7690

Pediatric Malignancies

Our laboratory is investigating the impact of S1P and other bioactive sphingolipids in pediatric cancer. We have found that plant-type sphingolipids called sphingadienes are capable of inhibiting the growth of neuroblastoma cells in culture and can reduce their ability to form tumors. We have also recently discovered a novel  S1P-regulated gene that has a powerful effect on the growth of cancer cells derived from highly malignant pediatric tumors including neuroblastoma and rhabdomyosarcoma. By studying this gene and its function in normal and malignant cells, we hope to identify the mechanism by which it promotes the growth of cancer cells and facilitates their ability to form tumors. This information could lead to the development of new therapeutic strategies targeting S1P and its downstream cancer-related genes to treat pediatric malignancies.

(below: classical rosette pattern of neuroblastoma tumor. Courtesy Elaine Cham, MD)

Revised: July 10, 2018 10:24 AM


© 2005 Children's Hospital Oakland Research Institute
5700 Martin Luther King Jr Way • Oakland, California 94609
Phone 510-450-7600 • Fax 510-450-7910
Site MapDisclaimer